Pfizer’s anti-COVID pill Paxlovid shows no benefit for younger adults

Pfizer’s anti-COVID pill Paxlovid shows no benefit for younger adults

The report’s authors found that Pfizer’s antiviral medication Paxlovid offered little to no benefit for younger adults. However, it did reduce the risk of hospitalization for high-risk seniors. Notably, supplementary material from the original study of Paxlovid in high-risk non-hospitalized adults with COVID-19 during the Delta wave had demonstrated benefits in those younger than 65, albeit the difference compared to the placebo was much less than in those 65 and older.

Among those over 65, there was a 73 percent decrease in the hospitalization rate and a 79 percent reduction in the risk of death. However, patients between the ages of 40 and 65 saw no benefit in taking the antiviral medication in either category, regardless of previous immunity status.

Another critical study from Hong Kong published in Lancet Infectious Diseases on the same day as the Israeli study but which went unmentioned in the press offered further evidence of Paxlovid’s limited therapeutic role. The authors reviewed their clinical experience with Paxlovid and Lagevrio, Merck’s antiviral pill, Molnupiravir, in hospitalized patients. They compared them to hospitalized patients who did not receive those medications during the horrific wave of infections that slammed into the semi-autonomous region in February and March.

The mortality risk reduction for Lagevrio was 52 percent, and for Paxlovid it was 66 percent. Those receiving antivirals had a lower risk of their disease progressing, but the drugs did not significantly impact their need for mechanical ventilation or ICU admission. The patients in the study averaged in age from mid-70s to early 80s.

Given the results of these studies, it bears mentioning that the Centers for Disease Control and Prevention (CDC) has recently estimated that approximately 95 percent of Americans aged 16 and older have some level of immunity against COVID-19.

Why America Doesn’t Trust the CDC

Why America Doesn’t Trust the CDC

Most remarkably, it didn’t seem to matter to the CDC that 75.2 percent of children under age 11 already have natural immunity, according to a CDC study that concluded in February. Natural immunity is certainly much more prevalent today, given the ubiquity of the Omicron variant since February. CDC data from New York and California demonstrated that natural immunity was 2.8 times more effective in preventing hospitalization and 3.3 to 4.7 times more effective in preventing COVID infection compared to vaccination during the Delta wave. These findings are consistent with dozens of other clinical studies. Yet natural immunity has consistently and inexplicably been dismissed by the medical establishment.

Public health officials are expected to recommend COVID vaccines for children under 5 as soon as June 21st, despite the fact that the vast majority of children already have natural immunity. In a recent Kaiser survey, only 18 percent of parents said they were eager to vaccinate their child in that age group.

Omicron pioneer Dr Angelique Coetzee pressured by world powers to exaggerate its seriousness

Omicron pioneer Dr Angelique Coetzee pressured by world powers to exaggerate its seriousness

“But I have stated many times before it can be a serious illness if you are unvaccinated and have comorbidities but for the majority of people it is a mild illness. I am the one who has seen the patients first-hand but the politicians won’t listen.”


Video source: The Jimmy Dore Show on YouTube

Some scientists warn that too many shots might actually harm the body’s ability to fight the Covid-19 virus.

Israel Considers 4th Vaccine Dose, but Some Experts Say It’s Premature.

Some scientists warn that too many shots might actually harm the body’s ability to fight the Covid-19 virus. But Israeli experts say there isn’t time to wait.

The proposal to give a fourth dose to those most at risk drew criticism from other scientists and medical professionals, who said it was premature and perhaps even counterproductive. Some experts have warned that too many shots eventually may lead to a sort of immune system fatigue, compromising the body’s ability to fight the virus.

While there is evidence that Omicron, discovered just last month, usually causes milder illness than earlier variants, Israeli officials said that by the time they have clearer information, it might be too late to protect the people most at risk.

Prof. Hagai Levine, an epidemiologist and chairman of the Israel Association of Public Health Physicians, said that Israel was not seeing a sharp rise in infections yet — daily infections are at around 1,200 a day, down from 11,000 at the peak of the Delta wave in August — and there was no evidence that a fourth shot was needed to prevent severe illness from Omicron.

Decreasing antibodies over time is natural, he said, and boosting antibodies may have limited benefit.